A “miracle” study announces a 100% effective treatment against cancer – Ouest-France

The American study, presented on Sunday June 5 at the ASCO cancerology congress (in Chicago, in the United States) and published the same day in the New England Journal of Medicine, is striking. Remission 6 to 25 months after treatment All patients treated for non-metastatic rectal cancer with dostarlimab, an immunotherapy drug produced by a biotech acquired by the giant GSK, are in remission six to 25 months after treatment. treatment. And with much better tolerance than the standard treatment based on radiochemotherapy and surgery. The study concerns only eighteen patients (twelve of whom received this product). It was not easy to launch, underlines one of the authors, Dr. Andrea Cercek, of Memorial Sloan Kettering Cancer (State of New York), since therapeutic solutions, imperfect but effective, existed. A revolution ? Beyond the small number, which requires that the results must be replicated to be validated, the patients concerned were affected by specific tumours: “With microsatellite instability, which concerns 5% of rectal tumours. We know that it is a good marker of the effectiveness of this type of immunotherapy. It has even become the standard of treatment in the disease at its advanced stage, underlines Dr. Esma Saada-Bouzid (from the Antoine Lacassagne Center in Nice) who did not participate in the study. If the results are confirmed, this will revolutionize the treatment of this subgroup of colorectal cancers. This tumor abnormality is found more frequently in colorectal cancers, but it also exists in other cancers. “Should we look for it in all tumours, from the curable stage”, asks Dr. Saada-Bouzid? A “miracle” study announces a 100% effective treatment against cancerEXPAND